Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | PRKACG | P22612 | 1/20 | 0.31 |
| ▸ | PRKACB | P22694 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24939857 | 0.90 | AHCY (0.35) | CDK2CCNE1CDK1AHCYCCNB1 | |
| SCHEMBL21101442 | 0.83 | CDK2 (0.47) | CDK2CCNE1CCNE2CDK1CCNB1 | |
| SCHEMBL21101704 | 0.79 | CCNE2 (0.36) | CDK2CCNE1CCNE2 | |
| SCHEMBL21101702 | 0.79 | CCNE2 (0.36) | CDK2CCNE1CCNE2 | |
| SCHEMBL22224576 | 0.79 | CDK2 (0.44) | CDK2CCNE1CCNE2CDK1CCNB1 | |
| SCHEMBL21136339 | 0.77 | CDK2 (0.40) | CDK2CCNE1CCNE2CDK1AHCY | |
| SCHEMBL19644902 | 0.75 | CCNE2 (0.42) | CDK2CCNE1CCNE2CDK1NT5E | |
| SCHEMBL21101450 | 0.75 | CCNE2 (0.42) | CDK2CCNE1CCNE2CDK1NT5E | |
| SCHEMBL19644706 | 0.75 | CDK2 (0.49) | CDK2CCNE1CCNE2CDK1CCNB1 | |
| SCHEMBL19370341 | 0.73 | NT5E (0.56) | CDK2CCNE1CCNE2CDK1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CDK2 1333/4885CCNE1 3374/4885CCNE2 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.